Immunomodulators: Use in combined therapy against leishmaniasis

Expert Review of Anti-Infective Therapy

Volumn 8, Issue 7, 2010, Pages 739-742

  Dalton, Jane E ^a   Kaye, Paul M ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY; IMIQUIMOD; IMMUNOMODULATING AGENT; MEGLUMINE ANTIMONATE; MILTEFOSINE; PAROMOMYCIN; PLACEBO; RECOMBINANT GAMMA INTERFERON; STIBOGLUCONATE SODIUM; SUNITINIB;

ANTIBIOTIC RESISTANCE; CHEMOTHERAPY; DRUG EFFICACY; DRUG POTENTIATION; DRUG USE; EDITORIAL; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LEISHMANIASIS; LYMPHOCYTE ACTIVATION; NONHUMAN; SKIN LEISHMANIASIS; T LYMPHOCYTE; TREATMENT RESPONSE; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIPROTOZOAL AGENTS; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOLOGIC FACTORS; LEISHMANIASIS;

EID: 77954232760     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.10.64     Document Type: Editorial

References (34)

1. Tripathi P, Singh V, Naik S. Immune response to leishmania: paradox rather than paradigm. FEMS Immunol. Med. Microbiol. 51(2), 229-242 (2007).
2. Goto H, Lindoso JA. Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev. Anti Infect. Ther. 8(4), 419-433 (2010).
3. Alvar J, Yactayo S, Bern C. Leishmaniasis and poverty. Trends Parasitol. 22(12), 552-557 (2006).
4. Chappuis F, Sundar S, Hailu A et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat. Rev. Microbiol. 5(11), 873-882 (2007). (Pubitemid 47578388)
5. Kaye PM, Svensson M, Ato M et al. The immunopathology of experimental visceral leishmaniasis. Immunol. Rev. 201, 239-253 (2004).
6. Davies CR, Kaye P, Croft SL, Sundar S. Leishmaniasis: new approaches to disease control. Br. Med. J. 326(7385), 377-382 (2003).
7. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet 366(9496), 1561-1577 (2005).
8. Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N. Engl. J. Med. 362(6), 504-512 (2010).
9. van Griensven J, Balasegaram M, Meheus F, Alvar J, Lynen L, Boelaert M. Combination therapy for visceral leishmaniasis. Lancet Infect. Dis. 10(3), 184-194 (2010).
10. Alvar J, Croft S, Olliaro P. Chemotherapy in the treatment and control of leishmaniasis. Adv. Parasitol. 61, 223-274 (2006).
11. Murray HW, Delph-Etienne S. Roles of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis. Infect. Immun. 68(1), 288-293 (2000).
12. Murray HW. Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob. Agents Chemother. 45(8), 2185-2197 (2001).
13. Fernandez-Guerrero ML, Aguado JM, Buzon L et al. Visceral leishmaniasis in immunocompromised hosts. Am. J. Med. 83(6), 1098-1102 (1987).
14. Murray HW, Oca MJ, Granger AM, Schreiber RD. Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis. J. Clin. Invest. 83(4), 1253-1257 (1989).
15. Murray HW, Berman JD, Wright SD. Immunochemotherapy for intracellular leishmania donovani infection: gamma interferon plus pentavalent antimony. J. Infect. Dis. 157(5), 973-978 (1988).
16. Sundar S, Rosenkaimer F, Murray HW. Successful treatment of refractory visceral leishmaniasis in India using antimony plus interferon-gamma. J. Infect. Dis. 170(3), 659-662 (1994).
17. Badaro R, Falcoff E, Badaro FS et al. Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. N. Engl. J. Med. 322(1), 16-21 (1990).
18. Nabors GS, Afonso LC, Farrell JP, Scott P. Switch from a type 2 to a type 1 T helper cell response and cure of established leishmania major infection in mice is induced by combined therapy with interleukin 12 and Pentostam. Proc. Natl Acad. Sci. USA 92(8), 3142-3146 (1995).
19. Murray HW, Montelibano C, Peterson R, Sypek JP. Interleukin-12 regulates the response to chemotherapy in experimental visceral leishmaniasis. J. Infect. Dis. 182(5), 1497-1502 (2000).
20. Tomai MA, Miller RL, Lipson KE, Kieper WC, Zarraga IE, Vasilakos JP. Resiquimod and other immune response modifiers as vaccine adjuvants. Expert Rev. Vaccines 6(5), 835-847 (2007).
21. Hemmi H, Kaisho T, Takeuchi O et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3(2), 196-200 (2002).
22. Miranda-Verastegui C, Tulliano G, Gyorkos TW et al. First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony. PLoS Negl. Trop. Dis. 3(7), e491 (2009).
23. Badaro R, Nascimento C, Carvalho JS et al. Recombinant human granulocyte-macrophage colony-stimulating factor reverses neutropenia and reduces secondary infections in visceral leishmaniasis. J. Infect. Dis. 170(2), 413-418 (1994).
24. Zubairi S, Sanos SL, Hill S, Kaye PM. Immunotherapy with OX40L-Fc or anti-CTLA-4 enhances local tissue responses and killing of Leishmania donovani. Eur. J. Immunol. 34(5), 1433-1440 (2004).
25. Murray HW, Lu CM, Brooks EB, Fichtl RE, DeVecchio JL, Heinzel FP. Modulation of T-cell costimulation as immunotherapy or immunochemotherapy in experimental visceral leishmaniasis. Infect. Immun. 71(11), 6453-6462 (2003).
26. Murphy ML, Cotterell SE, Gorak PM, Engwerda CR, Kaye PM. Blockade of CTLA-4 enhances host resistance to the intracellular pathogen, Leishmania donovani. J. Immunol. 161(8), 4153-4160 (1998).
27. Schonfeld D, Matschiner G, Chatwell L et al. An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies. Proc. Natl Acad. Sci. USA 106(20), 8198-8203 (2009).
28. Tugues S, Fernandez-Varo G, Munoz-Luque J et al. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology 46(6), 1919-1926 (2007).
29. Buysschaert I, Carmeliet P, Dewerchin M. Clinical and fundamental aspects of angiogenesis and anti-angiogenesis. Acta Clin. Belg. 62(3), 162-169 (2007).
30. Dalton JE, Maroof A, Owens BM et al. Inhibition of receptor tyrosine kinases restores immunocompetence and improves immune-dependent chemotherapy against experimental leishmaniasis in mice. J. Clin. Invest. 120(4), 1204-1216 (2010).
31. Wilson ME, Young BM, Davidson BL, Mente KA, McGowan SE. The importance of TGF-beta in murine visceral leishmaniasis. J. Immunol. 161(11), 6148-6155 (1998).
32. Murray HW, Lu CM, Mauze S et al. Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect. Immun. 70(11), 6284-6293 (2002).
33. Murray HW. Interleukin 10 receptor blockade - pentavalent antimony treatment in experimental visceral leishmaniasis. Acta Trop. 93(3), 295-301 (2005).
34. Murray HW, Flanders KC, Donaldson DD et al. Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis. Infect. Immun. 73(7), 3903-3911 (2005).